期刊
ORPHANET JOURNAL OF RARE DISEASES
卷 16, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s13023-021-01940-z
关键词
Zellweger spectrum disorder; Zellweger disease; Peroxisome biogenesis disorder; Hepatic injury; Cholic acid therapy
资金
- Travere Therapeutics, Inc.
Zellweger spectrum disorders (ZSDs) are rare, autosomal recessively inherited disorders characterized by peroxisomal dysfunction. Liver disease is a major contributor to morbidity and mortality in patients with ZSDs, and Cholbam has been shown to be a safe and effective treatment for improving liver function in these patients. It is recommended to initiate Cholbam therapy early in patients without advanced liver disease to prevent systemic impacts of hepatic damage.
Background Zellweger spectrum disorders (ZSDs) are a rare, heterogenous group of autosomal recessively inherited disorders characterized by reduced peroxisomes numbers, impaired peroxisomal formation, and/or defective peroxisomal functioning. In the absence of functional peroxisomes, bile acid synthesis is disrupted, and multisystem disease ensues with abnormalities in the brain, liver, kidneys, muscle, eyes, ears, and nervous system. Main body Liver disease may play an important role in morbidity and mortality, with hepatic fibrosis that can develop as early as the postnatal period and often progressing to cirrhosis within the first year of life. Because hepatic dysfunction can have numerous secondary effects on other organ systems, thereby impacting the overall disease severity, the treatment of liver disease in patients with ZSD is an important focus of disease management. Cholbam (R) (cholic acid), approved by the U.S. Food and Drug Administration in March 2015, is currently the only therapy approved as adjunctive treatment for patients with ZSDs and single enzyme bile acid synthesis disorders. This review will focus on the use of CA therapy in the treatment of liver disease associated with ZSDs, including recommendations for initiating and maintaining CA therapy and the limitations of available clinical data supporting its use in this patient population. Conclusions Cholbam is a safe and well-tolerated treatment for patients with ZSDs that has been shown to improve liver chemistries and reduce toxic bile acid intermediates in the majority of patients with ZSD. Due to the systemic impacts of hepatic damage, Cholbam should be initiated in patients without signs of advanced liver disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据